Arginase inhibition improves microvascular endothelial function in patients with type 2 diabetes mellitus

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 11, 2016, Pages 3952-3958

  Kövamees, Oskar ^a   Shemyakin, Alexey ^a   Checa, Antonio ^b   Wheelock, Craig E ^b   Lundberg, Jon O ^b   Östenson, Claes Göran ^a   Pernow, John ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; AMINO ACID; ARGINASE; ARGININE DERIVATIVE; CITRULLINE; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; ORNITHINE; ARGININE; CARDIOVASCULAR AGENT; ENZYME INHIBITOR; N(OMEGA)-HYDROXYNORARGININE; VASODILATOR AGENT;

AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CAPILLARY ENDOTHELIAL CELL; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GROUPS BY AGE; HUMAN; IONTOPHORESIS; LASER DOPPLER FLOWMETRY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; VASODILATATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BLOOD; COMPLICATION; CONTROLLED CLINICAL TRIAL; DIABETIC ANGIOPATHIES; DRUG EFFECTS; METABOLISM; MICROVASCULATURE; MIDDLE AGED; PATHOPHYSIOLOGY; PERIPHERAL VASCULAR DISEASES; SEVERITY OF ILLNESS INDEX; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE;

ACETYLCHOLINE; AGED; ARGINASE; ARGININE; CARDIOVASCULAR AGENTS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; FEMALE; HUMANS; LASER-DOPPLER FLOWMETRY; MALE; MICROVESSELS; MIDDLE AGED; NITROPRUSSIDE; ORNITHINE; PERIPHERAL VASCULAR DISEASES; SEVERITY OF ILLNESS INDEX; VASCULAR RESISTANCE; VASODILATION; VASODILATOR AGENTS;

EID: 84994803445     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2016-2007     Document Type: Article

References (31)

1. Moreno PR, Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol. 2004;44:2293-2300.
2. Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clustering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med. 1989;320:1161-1165.
3. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med. 1993;329:977-986.
4. Meyer MF, Schatz H. Influence of metabolic control and duration of disease on microvascular dysfunction in diabetes assessed by laser Doppler anemometry. Exp Clin Endocrinol Diabetes. 1998;106: 395-403.
5. Jaap AJ, Shore AC, Stockman AJ, Tooke JE. Skin capillary density in subjects with impaired glucose tolerance and patients with type 2 diabetes. Diabet Med. 1996;13:160-164.
6. Rayman G, Malik RA, Sharma AK, Day JL. Microvascular response to tissue injury and capillary ultrastructure in the foot skin of type I diabetic patients. Clin Sci (Lond). 1995;89:467-474.
7. Brunner H, Cockcroft JR, Deanfield J, et al. Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases.Astatement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens. 2005;23:233-246.
8. Nguyen TT, Shaw JE, Robinson C, et al. Diabetic retinopathy is related to both endothelium-dependent and-independent responses of skin microvascular flow. Diabetes Care. 2011;34:1389-1393.
9. Schmiedel O, Schroeter ML, Harvey JN. Microalbuminuria in type 2 diabetes indicates impaired microvascular vasomotion and perfusion. Am J Physiol Heart Circ Physiol. 2007;293:H3424-H3431.
10. Sogawa K, Nagaoka T, Tanano I, et al. Association between diabetic retinopathy and flow-mediated vasodilation in type 2DM.Curr Eye Res. 2012;37:446-451.
11. Münzel T, Heitzer T, Harrison DG. The physiology and pathophysiology of the nitric oxide/superoxide system. Herz. 1997;22:158-172.
12. Pernow J, Jung C. Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal? Cardiovasc Res. 2013;98:334-343.
13. Durante W, Johnson FK, Johnson RA. Arginase: a critical regulator of nitric oxide synthesis and vascular function. Clin Exp Pharmacol Physiol. 2007;34:906-911.
14. Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J. 2012;33:829-837, 837a-837d.
15. Grönros J, Jung C, Lundberg JO, Cerrato R, Ostenson CG, Pernow J. Arginase inhibition restores in vivo coronary microvascular function in type 2 diabetic rats. Am J Physiol Heart Circ Physiol. 2011; 300:H1174-H1181.
16. Shemyakin A, Kövamees O, Rafnsson A, et al. Arginase inhibition improves endothelial function in patients with coronary artery disease and type 2 diabetes mellitus. Circulation. 2012;126:2943-2950.
17. Beleznai T, Feher A, Spielvogel D, Lansman SL, Bagi Z. Arginase 1 contributes to diminished coronary arteriolar dilation in patients with diabetes. Am J Physiol Heart Circ Physiol. 2011;300:H777-H783.
18. Kövamees O, Shemyakin A, Pernow J. Effect of arginase inhibition on ischemia-reperfusion injury in patients with coronary artery disease with and without diabetes mellitus. PLoS One. 2014;9: e103260.
19. Jörneskog G, Kalani M, Kuhl J, et al. Early microvascular dysfunction in healthy normal-weight males with heredity for type 2 diabetes. Diabetes Care. 2005;28:1495-1497.
20. Morris SJ, Shore AC, Tooke JE. Responses of the skin microcirculation to acetylcholine and sodium nitroprusside in patients with NIDDM. Diabetologia. 1995;38:1337-1344.
21. Hezel MP, Liu M, Schiffer TA, et al. Effects of long-term dietary nitrate supplementation in mice. Redox Biol. 2015;5:234-242.
22. Settergren M, Pernow J, Brismar K, Jörneskog G, Kalani M. Endothelin-A receptor blockade increases nutritive skin capillary circulation in patients with type 2 diabetes and microangiopathy. J Vasc Res. 2008;45:295-302.
23. Yamamoto-Suganuma R, Aso Y. Relationship between post-occlusive forearm skin reactive hyperaemia and vascular disease in patients with type 2 diabetes-a novel index for detecting micro-and macrovascular dysfunction using laser Doppler flowmetry. Diabet Med. 2009;26:83-88.
24. Pernow J, Jung C. The emerging role of arginase in endothelial dysfunction in diabetes. Curr Vasc Pharmacol. 2016;14:155-162.
25. Romero MJ, PlattDH,Tawfik HE, et al. Diabetes-induced coronary vascular dysfunction involves increased arginase activity. Circ Res. 2008;102:95-102.
26. Kim JH, Bugaj LJ, Oh YJ, et al. Arginase inhibition restores NOS coupling and reverses endothelial dysfunction and vascular stiffness in old rats. J Appl Physiol (1985). 2009;107:1249-1257.
27. Romero MJ, Platt DH, Caldwell RB, Caldwell RW. Therapeutic use of citrulline in cardiovascular disease. Cardiovasc Drug Rev. 2006; 24:275-290.
28. Kashyap SR, Lara A, Zhang R, Park YM, DeFronzo RA. Insulin reduces plasma arginase activity in type 2 diabetic patients. Diabetes Care. 2008;31:134-139.
29. Bivalacqua TJ, Hellstrom WJ, Kadowitz PJ, Champion HC. Increased expression of arginase II in human diabetic corpus cavernosum: in diabetic-associated erectile dysfunction. Biochem Biophys Res Commun. 2001;283:923-927.
30. Hadi HA, Suwaidi JA. Endothelial dysfunction in diabetes mellitus. Vasc Health Risk Manag. 2007;3:853-876.
31. Hamilton SJ, Watts GF. Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment. Rev Diabet Stud. 2013;10:133-156.